Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
Zenas stock sinks on autoimmune readout despite hitting endpoint
With the result falling short of the bar Amgen set in another study, investors sent Zenas’ share price down 48% to $18 in premarket trading.
Nick Paul Taylor
Jan 5, 2026 9:30am
Sanofi's 2nd autoimmune pact with AI biotech could reach $2.5B
Jan 5, 2026 7:30am
Yarrow blooms with $1.37B autoimmune thyroid disease deal
Dec 16, 2025 11:00am
'Unprecedented' data prime Kyverna for 1st autoimmune CAR-T drug
Dec 15, 2025 10:55am
Sana, CAMP4 ditch clinical-stage assets for preclinical hopefuls
Nov 7, 2025 8:13am
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
